Rewriting the backbone

Oligonucleotide drugs are short strands of DNA or RNA, and making them still relies on solid-phase chemistry from the 1980s — just as new therapies may need multiton quantities. Nature builds these chains from phosphorus in its P(V) state. The lab asked what happens if chemists do the same.

8 chapters ~13 min read 8 key papers
Graphical abstract of the Science review: phosphorothioate and modified sugar building blocks, a double-stranded oligonucleotide, a chart of approved oligonucleotide drugs from 1998 to 2023, and three panels labelled new chemistries, biocatalysis and process technologies.
Approved oligonucleotide drugs from fomivirsen (1998) onward, and three routes to making them at scale. Graphical abstract, Obexer, Nassir, Moody, Baran & Lovelock, Science 2024 (corrected 18 July 2024).
Milestones

Timeline

  1. 1955

    Todd

    First chemical oligonucleotide synthesis, using P(V) phosphorochloridates.

  2. 1960s–70s

    Khorana

    Protecting-group strategy for long oligonucleotides, including a 72-mer tRNA.

  3. 1980s

    Phosphoramidites

    P(III) reagents and automation give modern solid-phase synthesis.

  4. 1998

    Fomivirsen

    The first approved oligonucleotide drug.

  5. 2018

    Unlocking P(V)

    Limonene-derived Ψ reagents for stereopure phosphorothioates, with BMS.

    See the paper →
  6. 2021

    P(V) platform

    Three linkage types on a commercial synthesizer.

    See the paper →
  7. 2021

    Inclisiran

    Approval of a cholesterol-lowering siRNA marks a turn toward high-volume oligonucleotide drugs.

  8. 2023

    Enzyme cascade

    Lovelock, Moody and Obexer make fomivirsen in one pot, without chromatography.

    Read it ↗
  9. 2023

    GSK collaboration

    GSK begins working with Elsie Biotechnologies.

  10. 2024

    Elsie acquired

    GSK acquires Elsie for up to $50 million; Science review on manufacturing.

  11. 2025

    Stereoprobes

    P(V) probes find covalent TLCD1 inhibitors, with the Cravatt lab.

    See the paper →
Scroll sideways for more →
01 The problem

A drug class outgrowing its chemistry

Oligonucleotide medicines — antisense strands and siRNAs — switch genes down by pairing with their messages. Unlike most drugs, they do not have to bind the disease-related protein itself; they bind the mRNA that encodes it. Promising sequences can be predicted from the target gene, then tuned with chemical modifications and delivery vehicles.

The list of approved drugs has grown steadily since the first, fomivirsen, in 1998. Early therapies were mostly for rare diseases. The 2024 Science review co-authored with Sarah Lovelock’s group at Manchester points to the approval of inclisiran, a cholesterol-lowering siRNA acquired by Novartis, as a turning point: atherosclerotic cardiovascular disease affects about 30 million people in the United States alone and is the leading cause of mortality worldwide.

Figure 2 of the Science 2024 oligonucleotide manufacturing review: structures of approved therapeutic oligonucleotides, grouped as steric blockers, gapmers and siRNAs, with a key for backbone and sugar modifications. Inclisiran (2021) is among the double-stranded siRNAs.
Approved therapeutic oligonucleotides, as surveyed in 2024, grouped by how they work: steric blockers, gapmers and siRNAs. Colours and shapes mark backbone and sugar modifications. Inclisiran, the cholesterol-lowering siRNA approved in 2021, is in the bottom group.Figure 2 from Obexer, Nassir, Moody, Baran & Lovelock, “Modern approaches to therapeutic oligonucleotide manufacturing,” Science 2024 (corrected 18 July 2024), doi:10.1126/science.adl4015. © 2024 The Authors; exclusive licensee AAAS. Reproduced by the authors for this site.

The chemistry that makes them has changed far less. Nearly every oligonucleotide is still built one link at a time on a solid support by the phosphoramidite method, developed in the early 1980s by Caruthers, Beaucage and others. It is a triumph: as the lab’s 2021 Outlook puts it, its impact “cannot be overstated.” But the 2024 review warns that existing methods “are limited by their scalability and sustainability,” just as new therapies may need “multiton quantities.”

Graphical abstract: Modern Approaches to Therapeutic Oligonucleotide Manufacturing
The lab’s 2024 Science review (corrected 18 July 2024) surveys three ways forward: new chemistries, biocatalysis and process technologies. Graphical abstract from Modern Approaches to Therapeutic Oligonucleotide Manufacturing, Science 2024 · doi:10.1126/science.adl4015

The constraints are concrete. Solid-phase synthesis is limited to batches of less than 10 kilograms, because larger columns give nonlinear flow and lower purity. In-line monitoring is difficult, and large excesses of phosphoramidite building blocks are needed to keep couplings efficient. Washing away leftovers, then chromatographically removing impurities — depurinations, base modifications, cyanoethyl adducts and truncated sequences — consumes prohibitively large volumes of acetonitrile, about 1,000 kilograms per kilogram of oligonucleotide. Even after purification, RNA-based therapeutics on the market are typically produced at about 90% purity. For strands that contain phosphorothioate (PS) linkages, the chemistry also produces a complex mixture of 2n−1 stereoisomers, where n is the number of nucleotides.

02 The drugs

How a short strand becomes a medicine

Therapeutic oligonucleotides are chemically modified nucleic-acid analogues, typically about 20 nucleotides long. The most prevalent backbone change is the phosphorothioate linkage, in which a non-bridging oxygen of the phosphate is replaced by sulfur. PS linkages appear in nine FDA-approved therapeutics, including fomivirsen; they help the drug resist nucleases and enter cells, but they also make each phosphorus a stereocentre (denoted RP or SP) that can influence activity. Another common backbone is the charge-neutral phosphorodiamidate morpholino (PMO), used in eteplirsen, golodirsen, viltolarsen and casimersen for Duchenne muscular dystrophy. Common 2′-ribose substitutions — 2′-fluoro, 2′-O-methyl and 2′-O-methoxyethyl — improve metabolic stability and favour an RNA-like sugar shape; 5-methylation of pyrimidines in antisense strands can increase binding to the mRNA target.

Figure 1 of the Science 2024 review: common chemical modifications in approved oligonucleotide drugs, including phosphorothioate and morpholino backbones, 5-methyl-pyrimidine bases, and 2′-O-methyl, 2′-fluoro and 2′-O-methoxyethyl sugars.
The modifications that make a short strand into a drug: phosphorothioate and morpholino backbones, 5-methyl-pyrimidine bases, and 2′-ribose substituents. Each change is a manufacturing problem as well as a pharmacological one.Figure 1 from Obexer, Nassir, Moody, Baran & Lovelock, “Modern approaches to therapeutic oligonucleotide manufacturing,” Science 2024 (corrected 18 July 2024), doi:10.1126/science.adl4015. © 2024 The Authors; exclusive licensee AAAS. Reproduced by the authors for this site.
03 The idea

Nature chose phosphates

“Where there is life there is phosphorous.”

The lab’s 2021 Outlook, Nature Chose Phosphates and Chemists Should Too, starts from biology. Phosphate links are remarkably stable (the half-life of the DNA backbone to background hydrolysis is around 30 million years) yet enzymes can open them on demand. Nature makes and breaks them in phosphorus’s P(V) oxidation state.

Chemists began there too. Todd made the first oligonucleotide in 1955 with P(V) reagents; Khorana extended the chemistry to long strands, including a 72-mer tRNA. But P(V) couplings were sluggish. As the 2024 review puts it, although the earliest laboratory methods for forging these P–O bonds also used P(V), “it was cast away in the 1970s because of the superior coupling efficiency of P(III)-based reagents.” Letsinger’s move to more reactive P(III) reagents, and then the phosphoramidite method, took over. The price is an extra step in every cycle: the P(III) link has to be oxidized or sulfurized back to P(V).

Two rows of boxes: the P(III) phosphoramidite cycle of deprotect, couple, cap and oxidize or sulfurize, and the P(V) cycle of deprotect, couple and cap, with no oxidation step.
One cycle of chain growth. Working in P(V) removes the oxidation step and lets the reagent, not chance, set the stereochemistry at phosphorus.Diagram: Baran Lab website, simplified from Knouse et al., ACS Cent. Sci. 2021, Huang et al., Science 2021, and Obexer et al., Science 2024.

A first-principles analysis, the review argues, still favours P(V) if the reagents can be improved: the approach “would negate an oxidation step, avoid excessive protecting group chemistry, and possibly rely on more-stable monomeric precursors.”

04 The incumbent

Still the gold standard, and still hard to scale

Despite those limitations, phosphoramidite chemistry “remains the gold standard for oligonucleotide manufacture.” The ability to produce a 20-base strand in about 50% yield and about 90% purity is impressive, the review notes, “considering that the synthesis comprises ~80 chemical steps.” The method is also highly flexible: it can make oligonucleotides, and their conjugates, with diverse chemical modifications. A great deal of work has gone into modernizing it — recovering or replacing reagents and solvents, moving purification from reverse-phase to aqueous ion-exchange or hydrophobic-interaction chromatography, and even using sulfurization by-products to cap failure sequences and skip a step.

Figure 3 of the Science 2024 review: the solid-phase phosphoramidite cycle of deprotection, coupling, capping and oxidation or sulfurization, common oxidants and sulfurizing reagents, and a separate cycle for phosphorodiamidate morpholino (PMO) synthesis.
A, the solid-phase phosphoramidite cycle that still makes nearly every approved oligonucleotide drug. B, the related cycle used to build charge-neutral morpholino (PMO) backbones.Figure 3 from Obexer, Nassir, Moody, Baran & Lovelock, “Modern approaches to therapeutic oligonucleotide manufacturing,” Science 2024 (corrected 18 July 2024), doi:10.1126/science.adl4015. © 2024 The Authors; exclusive licensee AAAS. Reproduced by the authors for this site.

The key to scaling up, the review argues, is liquid-phase chemistry that can shed excess reagents without a solid support. An early example, high-efficiency liquid-phase oligonucleotide synthesis, grew a 20-mer on soluble polyethylene glycol at a 10-milligram scale, but needed about 80 isolation steps and large volumes of solvent. Ajinomoto Bio-Pharma Services later applied its Ajiphase technology — soluble anchors with long alkyl chains, originally developed for peptides — so that detritylation, coupling and oxidation or sulfurization can be telescoped in one pot, with only one precipitation per nucleotide. A 21-mer has been produced in 60% yield; PMOs have been made in 10-kilogram batches to support clinical trials; and the review reports that the FDA has approved manufacture of an undisclosed commercial oligonucleotide by this method. Other groups have used organic-solvent nanofiltration on branched polyethylene glycol supports, or assembled oligonucleotides from shorter fragments. A notable Biogen example built an 18-mer from tetramer and pentamer blocks on a 200-gram scale, in 49% overall yield and 80% purity, later improved to about 90% by tighter control of the couplings.

A further limitation is the lack of stereocontrol when PS linkages are made. Efforts to set that stereochemistry date back to the 1990s, with chiral phosphoramidite analogues that gave reasonable couplings but only modest control. A later breakthrough used non-nucleophilic activators to couple bicyclic oxazaphospholidine monomers on a solid support. Chiral phosphoric acid catalysts have also been used to control P(III) centres, so far for linear and cyclic dinucleotides. The review also notes a recent suggestion that batch-to-batch changes in diastereomeric composition could undermine clinical outcomes — one more reason to care about a stereodefined backbone.

05 The breakthrough

A reagent from orange peel

In 2018, with Bristol Myers Squibb, the lab described a family of P(V) reagents, called Ψ (psi), made from limonene. For a P(V) approach to be viable, the review argues, the reagents would need to be inexpensive, able to make more than one kind of P–X linkage, stable to air and moisture, and comparable in coupling efficiency to P(III).

Early pioneering studies by the Stec group had pointed to a heterocyclic oxathiaphospholane backbone, but the first-generation monomers were themselves made from P(III) precursors, needed chromatographic separation of diastereomers, and coupled poorly. A systematic redesign produced stable, crystalline reagents from inexpensive limonene, “readily available on a commodity scale in either enantiomer.” Each enantiomer installs a phosphorothioate link in a chosen configuration: “programmable, traceless, diastereoselective phosphorus-sulfur incorporation,” in the words of the 2018 Science paper. The only activator required for loading and coupling is the inexpensive amine base DBU. In an early proof of concept, a pentamer made with Ψ came out as a single stereoisomer, where the phosphoramidite method gave a mixture. Designer P(III) reagents for the same job need at least seven steps to make.

Graphical abstract: Unlocking P(V): Reagents for Chiral Phosphorothioate Synthesis
Unlocking P(V): reagents for chiral phosphorothioate synthesis (Science 2018). Graphical abstract from Unlocking P(V): Reagents for Chiral Phosphorothioate Synthesis, Science 2018 · doi:10.1126/science.aau3369

That first report was applied to small sequences and cyclic dinucleotides. It had not yet been put on an automated synthesizer, and other linkage types still required P(III) chemistry. Three years later a unified platform addressed those limits. Three new reagent systems — rac-Ψ, ΨO and Ψ2 — allowed programmable synthesis of chimeric oligonucleotides, bearing several kinds of phosphorus linkage, on commercial solid-phase synthesizers. The Ψ cycle forms the P–O bond directly in the P(V) state, so it “obviates the need for sulfur-based protecting groups and superfluous redox steps.” The (+)-Ψ and (−)-Ψ reagents install chiral PS linkages; ΨO, Ψ2 and rac-Ψ install phosphodiesters, phosphorodithioates and racemic PS motifs respectively. A follow-up in Org. Lett. introduced a cheaper reagent, Ψ-Br, and a more robust linker to lower the barrier to adoption.

Figure 5 of the Science 2024 review: the P(V) solid-phase cycle, four psi reagents that install chiral or racemic phosphorothioates, natural phosphates or phosphorodithioates, and a chimeric oligonucleotide containing five different linkage types.
The P(V) platform on a solid support: no oxidation step, bench-stable reagents, and stereocontrol set by which Ψ reagent is used. A single strand can carry five different linkage types in chosen places.Figure 5 from Obexer, Nassir, Moody, Baran & Lovelock, “Modern approaches to therapeutic oligonucleotide manufacturing,” Science 2024 (corrected 18 July 2024), doi:10.1126/science.adl4015. © 2024 The Authors; exclusive licensee AAAS. Reproduced by the authors for this site.
⚗ For chemists

What the Ψ platform changes — and what it does not

Stereocontrol is “entirely dictated by the reagent employed,” and coupling forms the P–O bond directly in the P(V) state, so the platform “eliminates one full step” of standard solid-phase synthesis (the phosphorus oxidation). Earlier P(V) attempts were limited to about 15-mers by 92–94% coupling efficiencies. The 2024 review is careful not to overclaim: because P(III) chemistry has had many decades of optimisation, “it generally proceeds in higher yields in comparison to P(V).” The distinctive advantage of the newer chemistry is the ability “to provide homogeneous, stereopure oligonucleotides.” The review also notes “near immediate adoption by pharmaceutical companies”: a Biogen patent on liquid-phase P(V) processes, locked-nucleic-acid P(V) monomers at the Roche Innovation Center, oligonucleotides and cyclic dinucleotides at Bristol Myers Squibb, and therapeutic nucleotides at Gilead, among other users. Sequences that bear several linkage types, “such as the siRNA inclisiran, are of high interest, and the P(V) platform described above is ideally suited to assemble these complex products.”

Graphical abstract: A P(V) Platform for Oligonucleotide Synthesis
A unified P(V) platform on a commercial automated synthesizer (Science 2021). Graphical abstract from A P(V) Platform for Oligonucleotide Synthesis, Science 2021 · doi:10.1126/science.abi9727
06 The other path

Enzymes, in one pot or many fragments

Biocatalysis is already routine in small-molecule manufacturing, and several complementary strategies are being pursued for oligonucleotides. The most popular so far are convergent chemoenzymatic approaches, in which shorter chemically made fragments are joined by DNA or RNA ligases. Impurities accumulate with each chemical nucleotide addition, so making and assembling shorter pieces can give a cleaner product in higher yield. Ligases activate a 5′-monophosphate with ATP or NAD; the 3′-hydroxyl of the next fragment then forms the new link and releases AMP.

Figure 6 of the Science 2024 review: ligase mechanism; DNA-ligase assembly of overlapping siRNA fragments; non-templated RNA-ligase joining; template-independent synthesis with terminal deoxynucleotidyl transferase; and a one-pot polymerase plus endonuclease V cascade.
A, how DNA and RNA ligases join fragments. B, assembly of siRNA products by a DNA ligase, relying on overlapping base pairs. C, non-templated ligation, which needs a temporary 3′-protecting group. D, template-independent extension by terminal deoxynucleotidyl transferase (TdT). E, a one-pot polymerase and endonuclease cascade that can accumulate the product without chromatography.Figure 6 from Obexer, Nassir, Moody, Baran & Lovelock, “Modern approaches to therapeutic oligonucleotide manufacturing,” Science 2024 (corrected 18 July 2024), doi:10.1126/science.adl4015. © 2024 The Authors; exclusive licensee AAAS. Reproduced by the authors for this site.

GSK has shown that single-stranded gapmers can be built from crude chemical fragments annealed to a complementary DNA template, so several pieces can be ligated in one reaction without protecting groups; fragments with insertions or deletions fail to anneal and can be filtered away, and the product can be released by heating at a purity that can make chromatography unnecessary. Almac, Alnylam and Ajinomoto have used double-stranded DNA ligases in a related way to assemble siRNAs, relying on overlapping base pairs rather than an extra template. Almac and Alnylam showed that up to six fragments, including therapeutically relevant modifications, can be ligated in one pot. Single-stranded RNA ligases can also join fragments, though the donor usually needs a temporary 3′-protecting group to prevent uncontrolled polymerisation.

A different dream is to grow a therapeutic strand from nucleotide monomers with enzymes alone. Terminal deoxynucleotidyl transferases (TdTs) are a leading candidate. In one recent study a TdT variant produced a 10-mer with an average coupling efficiency of 98.7% over ten cycles, but the scale was small and the method used a large excess of nucleotide monomers (250 equivalents). TdTs are also “poorly tolerant of common chemical modifications that are present in therapeutic sequences,” and will need extensive engineering. Poly(U) polymerases have been reported to be more tolerant of 2′-ribose modifications.

A more radical departure, reported in 2023 by Moody, Obexer and Lovelock — co-authors of the manufacturing review — replaces iterative extension and deprotection with a single biocatalytic cascade. A polymerase extends a self-priming hairpin template; an endonuclease V then cuts the product free and regenerates the template, so multiple cycles can run in one pot. The method produced clinically relevant molecules that combine phosphate and PS linkages with 2′-ribose modifications. As a showcase, the FDA-approved drug fomivirsen, which contains 20 PS linkages, was made in a reaction that consumed 90% of the available nucleotide building blocks; the product was isolated by filtration in 87% purity without chromatography. Enzymes reported so far tend to prefer RP linkages; a next step, the review notes, is to develop complementary catalysts for SP linkages.

07 Why it matters

From the lab to a company

The lab’s industrial partner from the start was Bristol Myers Squibb, whose chemists co-authored the 2018 and 2021 Science papers. Phil Baran and Kyle Knouse, first author of the 2018 paper, went on to co-found Elsie Biotechnologies in San Diego with Dillon Flood and Phil Dawson, a company based on this P(V) chemistry. In the competing-interests statement of the 2024 review, Baran is disclosed as a co-founder and shareholder of Elsie. The review itself is a survey of the manufacturing field — chemical synthesis, biocatalysis and process engineering — not an account of the company.

GSK began a research collaboration with Elsie in July 2023. In June 2024 it announced that it had acquired the company for up to $50 million (about £39 million), to integrate Elsie’s “oligonucleotide discovery, synthesis, and delivery technologies” into its own platform.

GSK announcement, 6 June 2024

“GSK accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies.”

Read the press release ↗
08 Where it’s going

Manufacturing at the scale of medicine

The 2024 review’s outlook is deliberately integrative. Further improvements, it argues, will come from combining the best parts of each approach: for example, moving P(V) chemistry — including the Ψ reagents — from solid to soluble supports, and pairing that with nanofiltration, or assembling P(V) fragments by the kind of convergent or enzymatic ligation already demonstrated for phosphoramidites. Large-scale manufacture will also need a secure, low-cost supply of nucleotide building blocks; P(V) methods are attractive here because they can be derived from renewable commodity chemicals such as limonene. Biocatalysts will have to be engineered to work on a broad range of modified substrates under process-viable conditions. The review even floats, as a longer-term possibility, applying these ideas to sequences of the length of mRNA vaccines and therapeutics (about 103 to 104 nucleotides).

The aim is not a single winning method but “an integrated portfolio of synthetic methods and manufacturing technologies” able to deliver the many kinds of oligonucleotide now moving through the pipeline, “toward the sustainable manufacture of diverse oligonucleotide products.” The 2021 Outlook ends with a phrase that sums up the lab’s view of P(V): the examples so far are “just the tip of the iceberg.”

See also how radical chemistry and electrochemistry are reshaping the rest of the lab’s work: radical cross-coupling and electrochemistry.

Go deeper

Key reading

Reviews and essential papers, picked as a path into the field.

Start here

Modern Approaches to Therapeutic Oligonucleotide Manufacturing

Obexer, R.; Nassir, M.; Moody, E. R. et al. · Science 2024
Start here

Nature Chose Phosphates and Chemists Should Too: How Emerging P(V) Methods Can Augment Existing Strategies

Knouse, K. W.; Flood, D. T.; Vantourout, J. C. et al. · ACS Cent. Sci. 2021 · Open access

Related papers

All lab papers tagged Oligonucleotides